Turnstone Biologics Inc

turnstonebio.com
Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Series A,B,C, IPO
Fund:
Compass Rose
Developing next-generation tumor infiltrating lymphocytes (TIL) therapies by selecting the most potent and tumor-reactive T cells for potential treatment across multiple solid tumors

Related news

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.